Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Riketron N** is a veterinary fixed-dose injectable antibacterial product containing sulfadimidine sodium and trimethoprim. Sulfadimidine inhibits bacterial dihydropteroate synthase and trimethoprim inhibits bacterial dihydrofolate reductase, producing sequential blockade of microbial tetrahydrofolate synthesis and a synergistic bactericidal effect. It is authorized for intramuscular or intravenous treatment of susceptible bacterial infections in cattle, horses, and pigs, including infections of the respiratory, gastrointestinal, urogenital, skin, and claw systems. The product is marketed as a 200 mg/ml sulfadimidine sodium plus 40 mg/ml trimethoprim solution for injection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Riketron N.